This article is a correction to:
Identification of DYNLT1 associated with proliferation, relapse, and metastasis in breast cancer
Sen Miao1†
Gaoda Ju2†
Chonghua Jiang3†Bing Xue1†Lihua Zhao1Rui Zhang1Han Diao1Xingzhou Yu1Linlin Zhang1Xiaozao Pan1Hua Zhang1Lijuan Zang4*Lei Wang5*
Tianhao Zhou6*- 1Department of Pathology, Affiliated Hospital of Jining Medical University, Jining, China
- 2Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China
- 3Department of Neurosurgery, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, China
- 4Department of Pathology Center, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- 5Department of Breast Surgery, Affiliated Hospital of Jining Medical University, Jining, China
- 6Department of Medical Oncology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
A corrigendum on
Identification of DYNLT1 associated with proliferation, relapse, and metastasis in breast cancer
by Miao, S., Ju, G., Jiang, C., Xue, B., Zhao, L., Zhang, R., Diao, H., Yu, X., Zhang, L., Pan, X., Zhang, H., Zang, L., Wang, L., and Zhou, T. (2023). Front. Med. 10:1167676. doi: 10.3389/fmed.2023.1167676
In the published article, there was an error in affiliation of Dr. Tianhao Zhou. Instead of “1 Department of Pathology, Affiliated Hospital of Jining Medical University, Jining, China; 5 Department of Breast Surgery, Affiliated Hospital of Jining Medical University, Jining, China; 6 Key Laboratory of Breast Cancer Prevention and Treatment of the Ministry of Education, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin, China; 7 Department of Medical Oncology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China”, it should be “6 Department of Medical Oncology, Shanghai First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: DYNLT1, breast cancer, biomarker, prognosis, immune checkpoint blocking therapy
Citation: Miao S, Ju G, Jiang C, Xue B, Zhao L, Zhang R, Diao H, Yu X, Zhang L, Pan X, Zhang H, Zang L, Wang L and Zhou T (2024) Corrigendum: Identification of DYNLT1 associated with proliferation, relapse, and metastasis in breast cancer. Front. Med. 11:1375203. doi: 10.3389/fmed.2024.1375203
Received: 23 January 2024; Accepted: 25 January 2024;
Published: 05 February 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Miao, Ju, Jiang, Xue, Zhao, Zhang, Diao, Yu, Zhang, Pan, Zhang, Zang, Wang and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tianhao Zhou, wwwzhou0809@163.com; Lei Wang, Wang198111lei@126.com; Lijuan Zang, Lou19941205@163.com
†These authors have contributed equally to this work